

RENALYTIX AI

Provider network agreement for KidneyIntelX™

April 15, 2020

Download [full announcement](#)

Agreement with Three Rivers Provider Network, the fastest growing US proprietary provider network

KidneyIntelX risk assessment testing now available to Three Rivers members and clients

Renalytix AI plc (LSE: RENX), the AIM-traded developer of clinical grade artificial intelligence *in vitro* diagnostics for kidney disease, announces that it has executed a provider network agreement with Three Rivers Provider Network, Inc. ("TRPN") to cover *KidneyIntelX* testing for kidney disease patients. Under the agreement, *KidneyIntelX* tests processed on eligible patients through the RenalytixAI Salt Lake City Utah clinical laboratory facility are now available to both TRPN members and clients.

Founded in 1996, TRPN is the largest and fastest growing proprietary provider organisation (PPO) network in the United States. A PPO contracts with providers, such as RenalytixAI and health insurance plans, to provide better healthcare value for their members.

The TRPN network is currently comprised of more than 1.5 million provider locations, including 5,000 hospitals and 100,000 ancillary care facilities, and more than 200 payers. Through their aggregation and contracting of care services at scale, PPO networks like TRPN can help to accelerate coverage and payment for newly launched tests, medical devices and pharmaceuticals, while maintaining acceptable levels of reimbursement. Over 100 million lives now have access to the TRPN network through Acute Care Hospitals, Surgery Centers, Network Physicians, Ancillary Facilities, MRI Centers, Laboratories, Radiology, Urgent Care Clinics, Home Health, DME, Chiropractors, Physical Therapy, and Mental Health.

Shelley Glick, RenalytixAI Vice President, Market Access, said:

"A provider agreement that supports insurance coverage for a novel prognostic testing solution such as KidneyIntelX is an important consideration for patients and doctors. PPOs are an important avenue for many Americans to get access to high quality healthcare. Partnering with an industry leader like Three Rivers is core to our strategy of providing broad population access to KidneyIntelX."

Under terms of the provider network agreement, members with Three Rivers Provider Network now have access to *KidneyIntelX* risk assessment testing. This agreement enables TRPN plan members and their covered clients to receive the benefit of *KidneyIntelX* testing as a participating service provider.

Enquiries

Renalytix AI plc

James McCullough, CEO

www.renalytixai.com

Via Walbrook PR

Stifel (Nominated Adviser & Joint Broker)

Tel: 020 7710 7600

Alex Price / Jonathan Senior / Ben Maddison (Investment Banking)

N+1 Singer (Nominated Adviser & Broker)

Tel: 020 7496 3000

Aubrey Powell / James White / George Tzimas (Corporate Finance)

Tom Salvesen / Mia Gardner (Corporate Broking)

Walbrook PR Limited

Paul McManus
Lianne Cawthorne

Tel: 020 7933 8780
renalytix@walbrookpr.com
Mob: 07980 541 893
07584 391 303

About Kidney Disease

Kidney disease is now recognised as a public health epidemic affecting over 850 million people globally. The Centers for Disease Control estimates there that 15% of United States adults or 37 million people currently have kidney disease. It is reported that 9 out of 10 adults with chronic kidney disease do not know they have it and 1 out of 2 people with very low kidney function who are not on dialysis do not know they have CKD*. Kidney disease is referred to as a "silent killer" because it often has no symptoms and can go undetected until a very advanced stage. Each year kidney disease kills more people than breast and prostate cancer. Every day 13 patients die in the United States while waiting for a kidney transplant.

*<https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html>

About RenalytixAI

RenalytixAI is a developer of artificial intelligence-enabled clinical *in vitro* diagnostic solutions for kidney disease, one of the most common and costly

chronic medical conditions globally. The Company's products are being designed to make significant improvements in kidney disease diagnosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit renalytixai.com